Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954877692> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2954877692 endingPage "S101" @default.
- W2954877692 startingPage "S101" @default.
- W2954877692 abstract "Liquid biopsy (LBx) testing is an emerging trend in oncology to evaluate biomarker status and determine eligibility for oncology therapies. In this study, we sought to determine how oncologists and pathologists perceive LBx for somatic mutation testing in non-small cell lung cancer (NSCLC) and understand the level of uptake in clinical practice to date. Primary research was conducted via qualitative telephone interviews with US oncologists and pathologists. An online syndicated quantitative survey and patient chart review was also conducted. Both academic and community oncologists are well-aware of LBx for primary oncogenic driver mutations and secondary adaptive resistance mutations in NSCLC, yet uptake is limited. In 2018, 5% of NSCLC patients received an LBx, an increase from 2% in 2017 and 1% in 2016. However, 34% of oncologists anticipated increasing LBx use in the next six months. The majority of LBx testing is single-gene tests, with EGFRm the most frequently tested marker; there is limited use of LBx next-generation sequencing panel testing within NSCLC. Accuracy and concordance to tissue biopsy is a primary barrier to LBx clinical uptake. Due to these concerns, labs often perform confirmatory tissue-based testing irrespective of LBx result. Stakeholders also highlight key variances in LBx advantages and barriers depending on clinical positioning. Insufficient tissue to perform biomarker testing, a potential value proposition for LBx, is estimated to occur in 12% of NSCLC cases. LBx adoption remains limited due to various challenges including accuracy concerns, payer coverage and necessity of tissue biopsy for cancer diagnosis and tumor histology. LBx value propositions and overall opportunity may vary depending on clinical positioning (i.e. 1L vs. 2L setting). Evidence demonstrating clinical validity and clinical utility is likely necessary to drive further clinical adoption." @default.
- W2954877692 created "2019-07-12" @default.
- W2954877692 creator A5025075837 @default.
- W2954877692 creator A5036582873 @default.
- W2954877692 creator A5042818680 @default.
- W2954877692 creator A5049650790 @default.
- W2954877692 creator A5087838085 @default.
- W2954877692 date "2019-05-01" @default.
- W2954877692 modified "2023-09-30" @default.
- W2954877692 title "PCN237 ADOPTION AND UPTAKE OF LIQUID BIOPSY-BASED NSCLC SOMATIC MUTATION TESTING IN THE US CLINICAL SETTING" @default.
- W2954877692 doi "https://doi.org/10.1016/j.jval.2019.04.358" @default.
- W2954877692 hasPublicationYear "2019" @default.
- W2954877692 type Work @default.
- W2954877692 sameAs 2954877692 @default.
- W2954877692 citedByCount "0" @default.
- W2954877692 crossrefType "journal-article" @default.
- W2954877692 hasAuthorship W2954877692A5025075837 @default.
- W2954877692 hasAuthorship W2954877692A5036582873 @default.
- W2954877692 hasAuthorship W2954877692A5042818680 @default.
- W2954877692 hasAuthorship W2954877692A5049650790 @default.
- W2954877692 hasAuthorship W2954877692A5087838085 @default.
- W2954877692 hasBestOaLocation W29548776921 @default.
- W2954877692 hasConcept C121608353 @default.
- W2954877692 hasConcept C126322002 @default.
- W2954877692 hasConcept C143998085 @default.
- W2954877692 hasConcept C160798450 @default.
- W2954877692 hasConcept C185592680 @default.
- W2954877692 hasConcept C2775934546 @default.
- W2954877692 hasConcept C2776256026 @default.
- W2954877692 hasConcept C2779529041 @default.
- W2954877692 hasConcept C2780673598 @default.
- W2954877692 hasConcept C2781197716 @default.
- W2954877692 hasConcept C55493867 @default.
- W2954877692 hasConcept C71924100 @default.
- W2954877692 hasConceptScore W2954877692C121608353 @default.
- W2954877692 hasConceptScore W2954877692C126322002 @default.
- W2954877692 hasConceptScore W2954877692C143998085 @default.
- W2954877692 hasConceptScore W2954877692C160798450 @default.
- W2954877692 hasConceptScore W2954877692C185592680 @default.
- W2954877692 hasConceptScore W2954877692C2775934546 @default.
- W2954877692 hasConceptScore W2954877692C2776256026 @default.
- W2954877692 hasConceptScore W2954877692C2779529041 @default.
- W2954877692 hasConceptScore W2954877692C2780673598 @default.
- W2954877692 hasConceptScore W2954877692C2781197716 @default.
- W2954877692 hasConceptScore W2954877692C55493867 @default.
- W2954877692 hasConceptScore W2954877692C71924100 @default.
- W2954877692 hasLocation W29548776921 @default.
- W2954877692 hasOpenAccess W2954877692 @default.
- W2954877692 hasPrimaryLocation W29548776921 @default.
- W2954877692 hasRelatedWork W1482345510 @default.
- W2954877692 hasRelatedWork W2520919442 @default.
- W2954877692 hasRelatedWork W2767675663 @default.
- W2954877692 hasRelatedWork W2811484474 @default.
- W2954877692 hasRelatedWork W2893982277 @default.
- W2954877692 hasRelatedWork W2989084682 @default.
- W2954877692 hasRelatedWork W3032419867 @default.
- W2954877692 hasRelatedWork W4282983770 @default.
- W2954877692 hasRelatedWork W4310490811 @default.
- W2954877692 hasRelatedWork W4379284398 @default.
- W2954877692 hasVolume "22" @default.
- W2954877692 isParatext "false" @default.
- W2954877692 isRetracted "false" @default.
- W2954877692 magId "2954877692" @default.
- W2954877692 workType "article" @default.